Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) are indolent non-Hodgkin lymphomas.
• Both subtypes are typically characterized as CD5 and CD10 negative.
• Recent scientific progress has significantly enhanced the diagnostic capabilities for these conditions.

Purpose of the Study:

• To highlight recent advances in the diagnosis of LPL and MZL.
• To discuss the evolving management strategies for LPL and MZL.
• To explore differential responses to novel therapeutic agents in LPL and MZL.

Main Methods:

• Review of recent scientific literature on LPL and MZL diagnosis and management.
• Analysis of treatment outcomes with conventional and novel therapies.
• Examination of ongoing clinical trials for LPL and MZL patients.

Main Results:

• Improved diagnostic accuracy for LPL and MZL.
• Similar management approaches (observation vs. systemic therapy) for asymptomatic vs. advanced stages.
• Differential patient responses observed with novel agents, including BTK inhibitor ibrutinib.

Conclusions:

• Despite similarities in diagnosis and initial management, LPL and MZL exhibit distinct clinical behaviors.
• Novel agents like ibrutinib demonstrate variable efficacy, necessitating further investigation.
• Active clinical trials offer promising therapeutic avenues for patients with LPL and MZL.